Neuroendocrine Tumor Diagnosis and Management: ⁶⁸Ga-DOTATATE PET/CT

Area of Science:

• Nuclear Medicine
• Oncology
• Radiology

Background:

• Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms.
• Accurate diagnosis and staging are crucial for effective patient management.
• Functional imaging plays a vital role in assessing NETs.

Purpose of the Study:

• To review the utility of ⁶⁸Ga tetraazacyclododecanetetraacetic acid-DPhe1-Tyr3-octreotate (DOTATATE) PET/CT in the management of well-differentiated neuroendocrine tumors (NETs).
• To highlight its role in diagnosis, treatment selection, and localization of unknown primary NETs.

Main Methods:

• Review of current literature and clinical guidelines regarding ⁶⁸Ga-DOTATATE PET/CT in NETs.
• Discussion of its application in initial diagnosis, patient stratification for peptide receptor radionuclide therapy (PRRT), and identifying primary tumor sites.

Main Results:

• ⁶⁸Ga-DOTATATE PET/CT is the preferred functional imaging modality for well-differentiated NETs.
• It is recommended by the National Comprehensive Cancer Network (NCCN) for NET management.
• Combined with FDG PET/CT, it helps assess tumor heterogeneity in G2 and G3 NETs.

Conclusions:

• ⁶⁸Ga-DOTATATE PET/CT is an essential tool for the comprehensive management of neuroendocrine tumors.
• Its integration with other imaging modalities like FDG PET/CT allows for personalized patient care.
• It facilitates improved diagnostic accuracy and therapeutic decision-making in NET patients.